Management of alcoholic hepatitis: Current concepts

Hetal A Karsan, Samir Parekh

Hetal A Karsan, Atlanta Gastroenterology Associates, Emory University, Atlanta, GA 30342, United States
Hetal A Karsan, Samir Parekh, Emory University Liver Transplant Program, Atlanta, GA 30322, United States

Author contributions: Karsan HA designed the original outline; both Karsan HA and Parekh S wrote the paper.

Correspondence to: Hetal Karsan, MD, FACG, FACP, Clinical Assistant Professor of Medicine, Atlanta Gastroenterology Associates, Emory University, 5671 Peachtree-Dunwoody Road, Suite 600, Atlanta, GA 30342, United States. hkarsan@hotmail.com
Telephone: +1-404-2579000 Fax: +1-404-8479792
Received: October 25, 2011 Revised: July 23, 2012 Accepted: November 14, 2012 Published online: December 27, 2012

Abstract
Alcoholic hepatitis is a devastating form of acute liver injury seen in chronic alcohol abusers with significant morbidity and mortality. It is a multisystem disease that is precipitated by ingesting large quantities of alcohol with genetic and environmental factors playing a role. Prognostic criteria have been developed to predict disease severity and these criteria can serve as indicators to initiate medical therapy. Primary therapy remains abstinence and supportive care, as continued alcohol abuse is the most important risk factor for disease progression. The cornerstone of supportive care remains aggressive nutritional support, and although acute alcoholic hepatitis has been extensively studied, few specific medical therapies have been successful. Corticosteroids remain the most effective medical therapy available in improving short term survival in a select group of patients with alcoholic hepatitis; however, the long-term outcome of drug therapies is still not entirely clear and further clinical investigation is necessary. While liver transplantation for acute alcoholic hepatitis have demonstrated promising results, this practice remains controversial and has not been advocated universally, with most transplant centers requiring a prolonged period of abstinence before considering transplantation. Extracorporeal liver support devices, although still experimental, have been developed as a form of liver support to give additional time for liver regeneration. These have the potential for a significant therapeutic option in the future for this unfortunately dreadful disease.

© 2012 Baishideng. All rights reserved.

Key words: Alcoholic hepatitis; Acute liver injury; Abstinence; Nutrition; Corticosteroids; Transplantation; Extracorporeal liver support

Peer reviewers: Juan Carlos Perazzo, MD, PhD, Professor, Department of Biological Sciences, Pathophysiology School of Pharmacy and Biochemistry, UBA, Junín 950, 5, Buenos Aires 1113, Argentina; Bernd Schnabl, MD, Assistant Professor, Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC0702, La Jolla, CA 92039, United States; Dr. Lang Zhuo, Department of Cell and Tissue Engineering, Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanas No. 04-16, Singapore 138669, Singapore

Karsan HA, Parekh S. Management of alcoholic hepatitis: Current concepts. World J Hepatol 2012; 4(12): 335-341 Available from: URL: http://www.wjgnet.com/1948-5182/full/v4/i12/335.htm DOI: http://dx.doi.org/10.4254/wjh.v4.i12.335

INTRODUCTION
Alcoholic hepatitis is a multi-system disease seen in patients who have abused large quantities of alcohol over an extended period of time, often years. The development of alcoholic hepatitis is complex and dependent on a variety of genetic and environmental factors. In general, men who ingest more than 100 g of ethanol daily for more than 5 years are at highest risk of developing alcoholic hepatitis; however, women may develop alcoholic hepatitis after ingesting smaller amounts of ethanol for shorter periods of time. Alcoholic hepatitis can adversely affect multiple organ systems: the gastrointestinal system, central nervous system, hematologic system, cardiovascular system, and renal system. Symptoms
alcoholic hepatitis is complete abstinence from alcohol consumption. Abstinence is the single most important factor in the prevention of disease progression and can improve survival. However, survival decreases with concurrent portal hypertension and cirrhosis. Furthermore, abstinence is crucial for those patients with advanced liver disease who may eventually require orthotopic liver transplantation. Several medications have been investigated in hopes of maintaining alcohol abstinence. Disulfiram was one of the first United States Food and Drug Administration approved agents; however, its use has largely been abandoned due to poor tolerability and lack of supporting data. Alternatively, short term treatment with the opioid antagonist naltrexone has been shown to reduce the risk of alcohol relapse. Similarly, acamprosate, an inhibitory neurotransmitter similar to gamma-aminobutyric acid, has been shown to decrease the rate of alcohol relapse and maintain abstinence. Nonetheless, some patients with alcoholic hepatitis will progress despite abstinence and supportive medical care. Thus, several potential therapies have been studied in an attempt to achieve a more favorable disease course.

Supportive care
In addition to abstinence, the most vital therapy for a patient with acute alcoholic hepatitis is supportive care. This includes intensive care unit monitoring and intubation for airway protection when appropriate, especially in the setting of advanced hepatic encephalopathy. Alcohol withdrawal must be treated with benzodiazepines as needed. Intravenous fluids should be administered with electrolyte, mineral and vitamin supplementation, including replacement of phosphate, potassium, magnesium, multivitamins, thiamine and folate. A single dose of vitamin K may be given, but will not correct the coagulopathy if due to underlying hepatic synthetic dysfunction. Administration of fresh frozen plasma should be reserved only for active hemorrhage.

Hepatotoxic medications should be avoided, as should nephrotoxic medications, including aminoglycosides, angiotensin converting enzyme inhibitors and non-steroidal anti-inflammatory medications. Sepsis is a common cause of mortality in these gravely ill patients; however, it is often difficult to determine the presence of concomitant infection, as fever and leukocytosis are often encountered in acute alcoholic hepatitis, even in the absence of infection. Accordingly, a vigilant search for infection with appropriate cultures, including diagnostic paracentesis is crucial.

Nutrition
Patients with severe protein-calorie malnutrition have been found to have a significantly higher mortality compared to those who are only mildly malnourished. In fact, hepatic dysfunction in alcoholics was initially thought to be due to nutritional deficiencies. Thus, supplemental nutrition with high-calorie, high-protein diets administered either enterally or parenterally to these malnourished patients was advocated at the outset in hopes to improve outcomes. However, subsequent clinical tri-
als of supplemental nutrition administered to patients with acute alcoholic hepatitis have not been shown to improve mortality in this disease. Despite these findings, high-calorie, high-protein formulations have been shown to improve nutritional parameters during the acute illness and high catabolic state. Therefore, it may be worthwhile to utilize supplemental enteral nutrition during the acute phase of illness, especially in anorexic patients who do not meet their calculated daily requirements. Newer and more expensive branched-chain amino acid formulations have been proposed to have a lower incidence of hepatic encephalopathy. However, even standard amino acid preparations have not been shown to cause hepatic encephalopathy in cirrhotic patients with portal hypertension. Thus, branched-chain amino acid formulations do not likely offer an efficacy advantage and given the large discrepancy in price, are not cost-effective. It is also important to replace deficiencies in certain vitamins and minerals, including vitamins A, D, pyridoxine, thiamine, folate and zinc.

**Corticosteroids**

In view of the dismal prognosis associated with alcoholic hepatitis, many drugs have been investigated as potential mediators to alter the clinical course of this disease. Due to their well-known anti-inflammatory effects, corticosteroids have been the most extensively studied medication in patients with alcoholic hepatitis, many randomized controlled trials have produced inconsistent results. Thus, in 1990, Imperiale et al. reviewed 11 of the earlier trials conducted between 1971 and 1989 in hopes of reaching a consensus statement on the efficacy of corticosteroids for the treatment of alcoholic hepatitis. In this landmark meta-analysis, steroids were determined to be most beneficial in a subset of patients with severe acute alcoholic hepatitis and spontaneous hepatic encephalopathy, reducing the risk of short-term mortality to 0.66 for a protective efficacy of 34%. In contrast, Christensen et al. determined that glucocorticoids had no statistically significant beneficial or harmful effect. This meta-analysis found a high probability of publication bias in this area and cautioned against the routine use of glucocorticoids in patients with acute alcoholic hepatitis. The most recent meta-analysis on this subject confirmed that while corticosteroids were not beneficial for all patients with alcoholic hepatitis, there was a survival benefit in patients with severe disease, defined as the presence of spontaneous hepatic encephalopathy and/or DF ≥ 32. In a reanalysis of individual data from the last three randomized placebo controlled trials of corticosteroids, Mathurin et al. found a significant increase in one month survival for patients with severe alcoholic hepatitis (DF ≥ 32) treated with steroids (85% vs 65%). Thus, five patients needed to be treated to prevent one death. In an attempt to predict those individuals not responding to corticosteroids, a recently developed model was created using six clinical variables to calculate a Lille score (www.lillemodel.com). After 7-d of corticosteroids, a Lille score > 0.45 indicates a poor response to therapy and a 6-mo mortality of > 75%.

In accord with the recommendations by the American College of Gastroenterology and AASLD, corticosteroids use cannot be supported in patients with alcoholic hepatitis with concomitant gastrointestinal hemorrhage, pancreatitis, active infection or renal failure, as these patients were excluded in many of the clinical trials advocating corticosteroid treatment. Prednisolone 40 mg per day orally for four weeks followed by a taper or discontinuation is favored over prednisone, which requires hepatic conversion to the active prednisolone.

Of note, corticosteroids have not been shown to improve long-term survival, as follow-up in clinical studies have rarely extended beyond a few months, due to the high initial mortality rate associated with this disease. In a study comparing prednisolone to enteral feedings for 28 d for severe alcoholic hepatitis, there was no significant difference between groups in the treatment phase (25% vs 31%, respectively). However, 37% of the survivors in the steroid group died during the one-year follow-up compared with 8% of the survivors in the enteral feeding group. Most of these deaths were due to infections. Thus, despite the many years of investigation, the long-term benefits of corticosteroids in severe alcoholic hepatitis remain unclear.

**Tumor necrosis factor alpha inhibition**

Pentoxifylline is an oral phosphodiesterase inhibitor which also decreases tumor necrosis factor alpha production, which is known to be elevated in patients with alcoholic hepatitis. In a randomized controlled trial with 101 patients with severe alcoholic hepatitis defined as a DF ≥ 32, pentoxifylline was given to 49 patients at a dose of 400 mg three times daily for 4 wk. The remaining 52 patients received placebo. As expected, the control group had a mortality rate of 46%, but the treatment group demonstrated a significant improvement in survival with a mortality rate of 25%. Moreover, the reduction in mortality appeared to correlate with a significantly lower incidence of hepatoportal syndrome in the pentoxifylline group compared to the control group (8% compared with 35%). The findings of this study are encouraging and need to be confirmed with long-term follow-up.

Other clinical trials investigating anti-tumor necrosis factor agents including infliximab and etanercept given in conjunction with corticosteroids for acute alcoholic hepatitis showed no mortality benefit.

**Phosphatidylcholine**

In an effort to prevent alcohol-induced hepatocyte mitochondrial dysfunction, supplementation with the phospholipid phosphatidylcholine has been studied. In alcohol-fed baboons, phosphatidylcholine prevented the progression of pericentral and interstitial fibrosis to septal fibrosis and cirrhosis. Currently, a large randomized controlled trial is under way in humans.
Colchicine has been examined in patients with cirrhosis due to its effects on collagen and hepatic fibrogenesis. Moreover, it inhibits leukocyte migration and function and has positive effects on cytokine production related to fibroblast proliferation. Consequently, a randomized controlled trial was conducted in a population of 72 hospitalized patients with severe alcoholic hepatitis. At the standard dose of 1 mg orally per day for 1 mo, colchicine had no beneficial effect on morbidity, mortality or biochemical tests of liver function.

Amlodipine
Calcium channel blockers have been shown to have a hepatoprotective effect in animal models of alcohol-induced liver injury. However, a randomized, double-blind, placebo-controlled trial showed no conclusive evidence that amlodipine benefits patients with acute alcoholic hepatitis.

Insulin and glucagon
Insulin and glucagon have been known to enhance hepatic regeneration after partial hepatectomy in experimental animals. An early randomized clinical trial involving 50 patients administered insulin and glucagon infusions for the treatment of acute alcoholic hepatitis showed promise. However, subsequent larger studies have failed to show a clinical benefit, including short-term or long-term survival benefit. In fact, significant hypoglycemia became problematic, which limited the utility of this intervention in acute alcoholic hepatitis.

Transplantation
In the setting of acute alcoholic hepatitis, orthotopic liver transplantation is highly controversial. Yet, patients receiving liver transplantation for this disease have generally resulted in good outcomes. In fact, it has been suggested that transplantation even for acute alcoholic hepatitis is successful with comparable outcomes to that of patients transplanted for decompensated alcoholic cirrhosis alone. Most recently, Mathurin et al. demonstrated an improved 6 mo survival in patients with a first episode of severe alcoholic hepatitis not responding to medical therapy who underwent early liver transplantation compared to those who did not (77% vs 23%). Conversely, other investigators demonstrated a poor prognosis after transplantation with rapidly progressive liver injury with active alcoholic liver disease. Combining the high risk of recidivism in patients with acute alcoholic hepatitis along with the national shortage of donor organs, orthotopic liver transplantation has not been advocated for acute alcoholic hepatitis.

Initially, there was hesitation to transplant patients for decompensated alcoholic cirrhosis due to the perception that the disease was self-inflicted and concerns about post-transplantation compliance. Nevertheless, it is now clear that in appropriately selected patients with decompensated alcoholic cirrhosis, orthotopic liver transplantation provides an excellent prognosis, with outcomes similar to other nonalcoholic chronic liver diseases. In these appropriately screened patients, recidivism after transplantation still occurs in one-fifth to one-half of patients, but only 5%-7% return to excessive drinking. The most predictive variable of recidivism has been proposed to be a period of abstinence before transplantation. A documented 6 mo of pre-transplantation

S-adenosyl-methionine
S-adenosyl-methionine (SAMe) helps to maintain mitochondrial glutathione stores in alcoholic liver disease. At a dosage of 1200 mg per day for 2 years, SAMe exhibited a decrease in mortality and a delay in transplantation exclusively in Child-Turcotte-Pugh class A and B cirrhosis. It has not been studied in acute alcoholic hepatitis.

Antioxidants
Vitamin E may have a beneficial antioxidant role in alcoholic liver disease, but the outcomes of trials have been disappointing. Milk thistle, which contains the antioxidant silymarin may provide a benefit, albeit small, in Child-Turcotte-Pugh class A alcoholic cirrhosis who continue to drink alcohol. Most recently, the antioxidant effect of N-acetylcysteine was used in conjunction with glucocorticoids in patients with severe alcoholic hepatitis and demonstrated an increased 1 mo survival, although 6 mo survival was not improved.

Propylthiouracil
Alcohol induces a hypermetabolic state with pericentral hypoxia, similar to that seen in hyperthyroidism. Propylthiouracil has been tried in the hopes of reversing this hypermetabolic response and curtailing hepatocellular damage. In a randomized controlled trial with 67 patients with severe alcoholic hepatitis, propylthiouracil at 300 mg per day for 6 wk had no benefit on morbidity or mortality. Subsequently, in a long-term randomized trial with 310 patients, propylthiouracil demonstrated a significant mortality benefit, especially in patients with the most severe alcoholic hepatitis (55% compared with 25% placebo). However, propylthiouracil only conferred a benefit to those who remained abstinent. Furthermore, concerns regarding propylthiouracil-induced hypothyroidism have diminished the fervor for the use of propylthiouracil in alcoholic hepatitis.

Anabolic steroids
Androgens have been studied in an effort to improve the general nutritional status of patients with alcoholic hepatitis. In a large, multicenter population of United States veterans, oxandrolone at a dose of 80 mg per day for 1 mo did not affect short-term survival, but did increase survival at 6 mo in a subgroup of patients with moderate, but not severe alcoholic hepatitis. Unfortunately, these results have been confirmed in subsequent studies. Hence, the use of oxandrolone for acute alcoholic hepatitis cannot be routinely recommended.

Colchicine
Colchicine has been examined in patients with cirrhosis due to its effects on collagen and hepatic fibrogenesis. Moreover, it inhibits leukocyte migration and function and has positive effects on cytokine production related to fibroblast proliferation. Consequently, a randomized controlled trial was conducted in a population of 72 hospitalized patients with severe alcoholic hepatitis. At
abstinence is usually required as a minimal criterion for liver transplantation listing[8]. Other factors including social support and functional level are also extremely important to maintain abstinence. Current endeavors are underway to incorporate multiple variables to better risk stratify patients and standardize selection criteria for orthotopic liver transplantation in this population of patients. It is conceivable similar criteria could be used to determine appropriate liver transplant candidacy in the setting of acute alcoholic hepatitis as well. Notwithstanding, it has been estimated that only 5% of patients with end stage liver disease related to alcohol are formally evaluated to be considered for liver transplantation[8].

**Extracorporeal liver support**

Although they are still experimental, extracorporeal liver support devices have been developed as a form of liver support to give additional time for liver regeneration. One approach utilizes membranes and adsorbents that can remove toxins associated with liver failure, similar to hemodialysis in patients with end-stage renal disease. This type of extracorporeal liver support with molecular adsorbent recirculating system (MARS) uses a dialysis module in which the patient’s blood is dialyzed across an albumin-impregnated membrane, where detoxification can occur. Substances larger than 50 kDa, such as growth factors and essential hormones, are not removed. This device has shown promise in patients with acute liver failure superimposed upon chronic liver disease[9]. Recently, the MARS treatment was performed on 8 patients with severe acute alcoholic hepatitis superimposed on biopsy-proven cirrhosis[10]. These patients received 3 to 12 courses of 6 h of MARS treatment and encouraging results were seen in liver biochemistry, renal function, encephalopathy and mortality. However, the lack of power in this study does not allow definite conclusions. Nonetheless, a multi-center, randomized clinical trial is under way to study the efficacy of MARS treatment in acute alcoholic hepatitis.

**CONCLUSION**

Alcoholic hepatitis is a severe form of acute liver injury associated with significant morbidity and mortality. Although, prognostic criteria have been developed to help predict disease severity, it remains a challenge to treat. However, the primary intervention remains abstinence, as this is the most important risk factor for disease progression and is required if transplantation is eventually needed. Vigilant supportive care and adequate nutrition is crucial to help overcome this devastating illness. Several medications have been studied in an effort to alter the clinical course of this disease. Corticosteroids have been effective in reducing the short-term mortality in a subset of patients with severe alcoholic hepatitis with hepatic encephalopathy. Pentoxifylline also confers a significant short-term benefit for severe alcoholic hepatitis. Of note, despite more than 30 years of randomized controlled trials, no specific pharmacologic agent has clearly demonstrated a long-term survival benefit. Though outcomes in patients receiving liver transplantation for alcoholic hepatitis are similar to those transplanted for nonalcoholic liver diseases, liver transplantation in this patient population remains highly controversial. Extracorporeal liver support devices are still in their developmental infancy and may be an option in the future.

**REFERENCES**

1. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Hepatology* 2010; 51: 307-328.
2. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology* 1978; 75: 193-199.
3. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chapat JC, Rueff B, Peyrard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. *Gastroenterology* 1996; 110: 1847-1853.
4. Pharmacotherapy for alcohol dependence. Available from: URL: http://www.nimh.nih.gov/ public-info/clinical-trials/alcohol.htm
5. Srisurapant M, Jarusuraisin N. Opioiod antagonists for alcohol dependence. *Cochrane Database Syst Rev* 2005; (1): CD001867.
6. Mason BJ. Acamprosate in the treatment of alcohol dependence. *Expert Opin Pharmacother* 2005; 6: 2103-2115.
7. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, Seefl LB, Sorell M, Tamburro C, Zetterman R. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. *Am J Clin Nutr* 1986; 43: 213-218.
8. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouser S, Schneider D, Tamburro C, Tosch T, Weesner R. VA Cooperative Study on Alcoholic Hepatitis. III. Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. *JPEN J Parenter Enteral Nutr* 1985; 9: 590-596.
9. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. *J Hepatol* 1985; 1: 141-151.
10. Achord JL. Malnutrition and the role of nutritional support in alcoholic liver disease. *Am J Gastroenterol* 1987; 82: 1-7.
11. Soberon S, Pauley MP, Duplantier R, Fan A, Halsted CH. Metabolic effects of enteral formula feeding in alcoholic hepatitis. *Hepatology* 1987; 7: 1204-1209.
12. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. *Lancet* 1980; 2: 1276-1277.
13. Porter HP, Simon FR, Pepe CE, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. *J Engl J Med* 1971; 284: 1350-1355.
14. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. *Ann Intern Med* 1971; 74: 311-321.
15. Campa JA, Hamlin EM, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. *Ann Intern Med* 1973; 79: 625-631.
16. Blitzer RL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. *Am J Dig Dis* 1977; 22: 477-484.
17. Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephal-
lopathic patients. *Am J Gastroenterol* 1978; 69: 443-449

18 Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. *Gastroenterology* 1978; 74: 169-173.

19 DePew W, Boyer T, Omata M, Redeker A, Reynolda T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. *Gastroenterology* 1980; 78: 524-529.

20 Theodossi A, Eddeleston AI, Williams R. Controlled trial of methylprednisolone therapy in severe acute hepatic failure. *Gut* 1982; 23: 75-79.

21 Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff L, Sorrell M, Tambarco C, Weesner R, Zetterman R. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. *N Engl J Med* 1984; 311: 1464-1470.

22 Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. *Ann Intern Med* 1989; 110: 685-690.

23 Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. *N Engl J Med* 1992; 326: 507-512.

24 Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. *Ann Intern Med* 1990; 113: 299-307.

25 Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. *Caf* 1995; 37: 113-118.

26 Rambaldi A, Sacanato HH, Christensen E, Thorlund K, Wetterles J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. *Aliment Pharmacol Ther* 2008; 27: 1167-1178.

27 Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. *J Hepatol* 2002; 36: 480-487.

28 Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Mathurin P, Seux F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Carvallo, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 2007; 45: 1348-1354.

29 McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. *Am J Gastroenterol* 1998; 93: 2022-2036.

30 Cabré E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sánchez-Lombrana JL, Parés A, Popa M, Planas R, Gassull MA. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. *Hepatology* 2000; 32: 36-42.

31 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; 119: 1637-1649.

32 Naveau S, Chollet-Martín S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broût P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. *Hepatology* 2004; 39: 1390-1397.

33 Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamaath PS, Shah VH. A randomized, double-blind, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. *Gastroenterology* 2008; 135: 1953-1960.

34 Lieder CS, DeCarli LM, Mak KM, Kim CL, Leo MA. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated oleic acid. *Hepatology* 1990; 12: 1390-1398.

35 Mato JM, Camara J, Fernandez de Paz J, Caballera L, Coll S, Caballero A, Garcia-Buey L, Beltrán J, Benita V, Caballera J, Solà R, Moreno-Otero R, Barrao F, Martin-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Redi S. S-adenosylmethionine in alcoholic cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol* 1999; 30: 1081-1089.

36 Butcher GP, Rhodes JM, Walker R, Krasner N, Jackson MJ. The effect of antioxidant supplementation on a serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. *J Hepatol* 1993; 19: 105-109.

37 Sadrzadeh SM, Meydani M, Khettry U, Nanji AA. High-dose vitamin E supplementation has no effect on ethanol-induced pathological liver injury. *J Pharmacol Exp Ther* 1995; 273: 455-460.

38 Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 1989; 9: 105-113.

39 Nguyen-Khac E, Thevenot T, Piquet MA, Benerhat S, Goria O, Chetaibok D, Doutray B, Dewaele F, Ghirib S, Rudier M, Carbonell N, Tosso U, Bentel A, Bernard-Chabert B, Dupas JL, Glucocorticoids plus N-acetyl cysteine in severe alcoholic hepatitis. *N Engl J Med* 2011; 365: 1781-1789.

40 Halle P, Paré P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. *Gastroenterology* 1982; 82: 925-931.

41 Orrego H, Blake JE, Blends LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. *N Engl J Med* 1987; 317: 1421-1427.

42 Akriviadis EA, Steindel H, Pinto PC, Fong TL, Kanel G, Reynolds TB, Gupta S. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. *Gas- troenterology* 1990; 99: 811-818.

43 Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh B. Randomised controlled double-blind trial of the calcium channel antagonist amldoline in the treatment of acute alcoholic hepatitis. *J Hepatol* 1998; 28: 194-198.

44 Baker AL, Jaspan JB, Haines NW, Hatfield GE, Krager PS, Schneider JF. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. *Gastroenterology* 1981; 80: 1410-1414.

45 Bird G, Lau JY, Koskins J, Wicks C, Williams R. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. *Hepatology* 1991; 14: 1097-1101.

46 Trinchet JC, Balkau B, Boupon RE, Heintzmann F, Callard P, Gotheil C, Grange JD, Vetter D, Pauwels A, Labadie H, Sadrzadeh SM, Theodossi A, DeCarli LM, Mak KM, Kim CL, Leo MA. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated oleic acid. *Hepatology* 1990; 12: 1390-1398.

47 Bonet H, Manez R, Kramer D, Wright HI, Gavaler JS, Badour N, Van Thiel DH. Liver transplantation for alcoholic liver disease: survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. *Alcohol Clin Exp Res* 1993; 17: 1102-1106.

48 Shakil AO, Pinna A, Dementis J, Lee RG, Fung JJ, Rakela J. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. *Liver Transpl Surg* 1997; 3: 240-244.

49 Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Leclercq C, Naveau S, Abdelnour M, Ramond MJ, Carithers RL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff L, Sorrell M, Tambarco C, Weesner R, Zetterman R. Short-term and long-term survival in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 1984; 39: 1390-1397.
Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvo FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med* 2011; 365: 1790-1800

50 Conjeevaram HS, Hart J, Lissoos TW, Schiano TD, Dasgupta K, Befeler AS, Mills JM, Baker AL. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. *Transplantation* 1999; 67: 1562-1568

51 Moss AH, Siegler M. Should alcoholics compete equally for liver transplantation? *JAMA* 1991; 265: 1295-1298

52 Gerhardt TC, Goldstein RM, Urschel HC, Tripp LE, Levy MF, Husberg BS, Jennings LW, Gonwa TA, Klintmalm GB. Alcohol use following liver transplantation for alcoholic cirrhosis. *Transplantation* 1996; 62: 1060-1063

53 Fábrrega E, Crespo J, Casafort F, De las Heras G, de la Peña J, Pons-Romero F. Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. *J Clin Gastroenterol* 1998; 26: 204-206

54 Osorio RW, Ascher NL, Avery M, Bacchetti P, Roberts JP, Lake JR. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. *Hepatology* 1994; 20: 105-110

55 Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. *Transplantation* 1998; 66: 956-962

56 O’Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet’s nest! *Gut* 2006; 55: 1529-1531

57 Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Löhr M, Liebe S, Schareck W, Hopt UT, Schmidt R. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. *Artif Organs* 1999; 23: 319-330

58 Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. *J Hepatol* 2003; 38: 24-31

**Karsan HA et al. Management of alcoholic hepatitis**